Sublime
An inspiration engine for ideas
Biotech dreams are dying killed by costs not lack of potential. But in the south,a revolution brews: trials 80% cheaper, labs a fraction of US rates, quality intact.
My article on why Argentina isnt just an exit,its a gateway to innovation $IBB $XBI
Link:https://t.co/f3wvPBYKVJ
Bursatil Biotechx.comMariana Glukman
@glukman
Altos Labs, which has raised $3 billion, more start-up funding than for any previous biotech venture, is one company seeking to find effective anti-aging technologies. Its chief scientist, Richard Klausner, argues, “We think we can turn back the clock” on human mortality. Focusing on techniques of “rejuvenation programming,” the company aims to res
... See moreMustafa Suleyman • The Coming Wave: Technology, Power, and the Twenty-first Century's Greatest Dilemma
John Larson
@jrl
I remember when Nektar’s program first sparked investor interest in modified IL-2 for onco… many other variations of their theme emerged since then. Some will say this is what’s wrong w/ biotech. Jake & I think it’s what’s great about of our ecosystem. https://t.co/IIKt9POTFB
Peter Kolchinskyx.comMaryus Martsyalis
@maryusmartsyalis
RNA therapeutics landscape (private and public). From Cowen's recent RNA review. https://t.co/UzJbS9E2AR
Max Olgin
@maximum360